Please login to the form below

Not currently logged in
Email:
Password:

Akinion’s Dr Richard Jones joins Holostem Terapie Avanzate

He takes on the role of chief executive officer

Holostem Terapie Avanzate Dr Richard JonesModena, Italy-based Holostem Terapie Avanzate has appointed Dr Richard Jones as its chief executive officer.

Dr Jones moves to the cell and gene therapy specialist from Swedish biotech Akinion Pharmaceuticals, where he had served as chief executive since January last year.

He brings over two decades of industry experience to the position, including from Novartis, where he was vice president and medicines commercialisation leader for haematology and global oncology.

Prior to this, Dr Jones served as vice president, global haematology medicines leader at GlaxoSmithKline, and has also held posts at Genzyme and Shire.

Dr Paolo Chiesi, chairman of the board at Holostem, said: “On behalf of the Holostem board, I am delighted to welcome Richard to the company.

“He brings a unique combination of international and rare disease expertise, crucial for this stage of Holostem's evolution.

“We look forward to working with Richard on the continued growth of the company's development and the realisation of the potential of the technology platform.”

2nd February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics